Brazil to import two million AstraZeneca vaccine doses, not yet approved for use

Importing the doses prior to approval will enable vaccination to begin as soon as Anvisa okays its use, the regulator said. Brazil has yet to approve any vaccine.

Reuters
January 03, 2021 / 09:21 PM IST

Reuters

Brazil's health regulator Anvisa said late on Saturday it had approved the import of 2 million doses of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, although the jab is not yet approved for use in the country.

Anvisa said it approved the importation request from federal government-affiliated biomedical center Fiocruz on Thursday.

Importing the doses prior to approval will enable vaccination to begin as soon as Anvisa okays its use, the regulator said. Brazil has yet to approve any vaccine.

Fiocruz will apply for emergency use of the vaccine by Wednesday, its president, Nísia Trindade, said last week.

Brazil has recorded the second-deadliest outbreak of COVID-19 after only the United States. South America's largest country has the third highest tally of coronavirus cases, with the health ministry registering more than 7.7 million, after the United States and India.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Follow our full coverage of the coronavirus pandemic here.
Reuters
TAGS: #AstraZeneca #Brazil #coronavirus #Covid-19 #World News
first published: Jan 3, 2021 09:20 pm